Ke Ben Mirae (Beijing) Biomedical Science Co., Ltd. 科本未来(北京)生物医药科技开发有限公司 MIRAE BIO MEDICINE Co., Ltd.

CEO: Choi Jun-wan
Capital: KRW 400 Billion

Endorsed by the Chinese government, this prestigious enterprise stands as Beijing's sole specialist in cellular technologies. It has been selected as a focal company for global expansion and is acclaimed as China's premier cellular enterprise. MIRAEBIO is at the forefront of cellular pharmaceuticals development and manages elite hospitals specializing in cellular therapies, collaborating with over 10,000 hospitals worldwide.

MIRAE BIO Co.,Ltd.
CEO: Choi Jun-wan

Strategically positioned as a hub targeting the Asian markets, the Hong Kong office is pivotal in our expansive network. Ambitious plans are set for further establishments in Japan, Singapore, Malaysia, Thailand, and India by 2026.

MIRAE N MEDI Co.,Ltd
CEO: Choi Jae-won

This technologically advanced enterprise excels in the direct manufacture, production, and distribution of specialized equipment. It globally exports an extensive range of 150 medical and cosmetic devices, setting industry standards in cellular technology equipment

MIRAE BIO MEDICINE Co.,Ltd.
CEO: Choi Jun-wan

With a venerable 23-year legacy in operating clinics and hospitals dedicated to cell therapy, this entity pioneers international ventures, both independently and through collaborations, featuring state-of-the-art GMP research facilities and therapeutic institutions

Directly managed hospitals and clinics maintain synergistic collaborations with over 400 tertiary and general hospitals, spearheading medical technology both domestically and internationally with more than 1,000 specialized physicians.

각Operating globally unique, government-sanctioned cellular-specialized facilities (GMP), which are the only ones to receive official accreditation for cellular research and disease treatment from three distinct countries: South Korea, Japan, and China.

A distinguished federation encompassing cellular-specialist enterprises, hospitals, and physicians across 64 countries. It collaborates globally with leading cellular specialists to advance clinical practices and forge new paradigms in cellular therapy through international conferences.